- Home
- Life Sciences
- Pharmaceutical
- Pharmaceutical Analysis & Statistics in Europe Countries, May 2013
Talk to Geoffrey
+1 718 618 4302
Search inside this page
Publication dates
Publishers
- Global Data (1 068)
- Business Monitor International (178)
- Global Research & Data Services (209)
- Euromonitor International (295)
- Global Markets Direct (321)
-
- Timetric (14)
- PMR Ltd. (26)
- Emerging Markets Direct Media Holdings (15)
- Euroresearch & Consulting (1)
- GBI Research (13)
- Global Industry Analysts (1)
- Ibisworld (8)
- Datamonitor (361)
- Mintel (168)
- MarketLine (127)
- Obainfo (59)
- Timely Data Resources Inc. (52)
- Espicom Business Intelligence (36)
- ICD Research (36)
- World Market Intelligence Ltd (33)
- ABMRG (15)
- Aruvian's R'search (14)
- VacZine Analytics Group Of Assay Advantage Ltd (14)
- DrugPatentWatch - ThinkBiotech LLC (13)
- SeeNews - Research & Profiles (13)
- SCRIP Insights (12)
- Business Review (11)
- Canadean Ltd (10)
- Global Industry Analyst (10)
- MarketLine Industry Guides (10)
- Databank - Cerved Group (9)
- Koncept Analytics (9)
- RNCOS (9)
- Life Science Analytics (LSA) (8)
- MarketsandMarkets (7)
- Daedal Research (6)
- Frost & Sullivan (6)
- Firstword Pharma (5)
- IndexBox Marketing (4)
- Visiongain (4)
- International Market Analysis Research and Consult (3)
- Ken Research Private (3)
- Key Note Publications Ltd (3)
- La Merie Publishing (3)
- Verdict Research Ltd (3)
- Barnes Reports (2)
- BusinesStat (2)
- CHI Insight Pharma Reports (2)
- Kalorama Information (2)
- Plimsoll Publishing Ltd UK (2)
- Sociable Pharma (2)
- IData Research, Inc. (2)
- Zzz- Median Conseil (2)
- Zzz- Sokrat Capital Ltd (2)
- Analytiqa (1)
- Arena (1)
- Arrowhead (1)
- Beremans Ltd (1)
- BioPharm Reports (1)
- Bioseeker (1)
- Freedonia (1)
- GS-Expert LLC (1)
- Greystone Research Associates (1)
- Industry Experts (1)
- Infomine Research Group (1)
- Leatherhead Food Research (1)
- Marketest (1)
- Renub Research (1)
- Urch Publishing (1)
All regions
- All
- Europe
- Albania (1)
- Austria (64)
- Belarus (23)
- Belgium (104)
- Bosnia and Herzegovina (8)
- Bulgaria (50)
- Croatia (37)
- Cyprus (4)
- Czech Republic (80)
- Denmark (120)
- Estonia (24)
- Finland (57)
- France (959)
- Germany (1 028)
- Greece (79)
- Hungary (76)
- Iceland (3)
- Ireland (83)
- Italy (915)
- Latvia (26)
- Liechtenstein (1)
- Lithuania (29)
- Luxembourg (2)
- Macedonia (16)
- Malta (1)
- Moldova, Republic Of (15)
- Monaco (1)
- Netherlands (162)
- Norway (71)
- Poland (115)
- Portugal (48)
- Romania (71)
- Russian Federation (194)
- San Marino (2)
- Serbia and Montenegro (29)
- Slovakia (slovak Republic) (35)
- Slovenia (37)
- Spain (896)
- Sweden (167)
- Switzerland (159)
- Ukraine (50)
- United Kingdom (1 005)
- Europe
data types
Free Market Research Guides to Download
Pharmaceutical Analysis & Statistics in Europe Countries, May 2013
You might be interested in: therapeutics, cancer, drug, more »
» Purchase Premium Reports
1-30 of about 3 300 reports
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Europe, United Kingdom
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : France, World, Spain, Italy, Germany, Japan, India, China, Europe, United States, United Kingdom
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Evista (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : United States, World, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Viviant/Combriza (Osteoporosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Spain, Italy, Japan, United States, World
Aprela (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Aprela (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Aprela (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : United States, World, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Romosozumab (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis ...
- Industries : Pathology
- Countries : United Kingdom
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and ...
- Industries : Pathology
- Countries : Germany
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - France Drug Forecast and ...
- Industries : Pathology
- Countries : France
PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market ...
- Industries : Pathology
- Countries : Spain
PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market ...
- Industries : Pathology
- Countries : Italy
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - United Kingdom Drug ...
- Industries : Pathology
- Countries : United Kingdom
PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis ...
- Industries : Drug and Medication
- Countries : France
PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis ...
- Industries : Drug and Medication
- Countries : Germany
PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis ...
- Industries : Drug and Medication
- Countries : Italy
PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis ...
- Industries : Drug and Medication
- Countries : Spain
PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- February 2013
- by Global Data
PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022?. ...
- Industries : Drug and Medication
- Countries : United Kingdom
Global Herbal Supplements and Remedies Industry
- $ 4 950
- Industry report
- March 2013
- by Global Industry Analysts
This report analyzes the worldwide markets for Herbal Supplements and Remedies in US$ Million by the following Product Segments: Ginkgo Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera, ...
- Industries : Vitamin and Supplement
- Countries : World, Japan, United States, Canada, Europe, South America, North America, Asia, France, Germany, China, United Kingdom, Spain, Italy
Vaccines - Top 10 Global Markets Package
- $ 5 174
- Industry report
- May 2013
- by Global Research & Data Services
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information ...
- Industries : Drug and Medication
- Countries : World, United States, United Kingdom, Russian Federation, Italy, France, Germany, Japan, India, China, Europe
MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts
- $ 4 450
- Industry report
- February 2013
- by Global Data
MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts Summary Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence ...
- Industries : Pathology
- Countries : Europe, Spain, Italy, France, Germany, United Kingdom, United States, World
EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022
- $ 3 995
- Industry report
- April 2013
- by Global Data
EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022 Summary Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth ...
- Industries : Pathology
- Countries : United States, Japan, World, Spain, Italy, France, Germany
PharmaFocus: Vaccine Adjuvants in Infectious Disease
- $ 3 995
- Industry report
- March 2013
- by Global Data
PharmaFocus: Vaccine Adjuvants in Infectious Disease Summary Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry's ?dirty little secret?. Today, ...
- Industries : Drug and Medication
- Countries : United States, World, United Kingdom, Sweden
EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022
- $ 3 995
- Industry report
- March 2013
- by Global Data
EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022 Summary Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the ...
- Industries : Pathology
- Countries : United States, France, Europe, United Kingdom, World, Spain, Italy, Germany
EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022
- $ 3 995
- Industry report
- March 2013
- by Global Data
EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022 Summary Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a multi-factorial disease of the eye caused by dryness, decreased ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, India, China
EpiCast Report: Psoriasis - Epidemiology Forecast to 2022
- $ 3 995
- Industry report
- March 2013
- by Global Data
EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 Summary Psoriasis is an immune-mediated chronic disorder of the skin characterized by redness and irritation. It affects people of both sexes ...
- Industries : Pathology
- Countries : India, Japan, China, World, United States, Asia, Europe, Spain, Italy, France, Germany
Russian pharma industry in details
- $ 3 750
- Industry report
- May 2013
- by Euroresearch & Consulting
Purpose of this report was to analyze Russian of pharma. Please pay attention: Benefits of buying the report: ? The report included large volume of information on Russian pharma industry. The report is ...
- Industries : Pharmacies and Drug Stores
- Countries : Russian Federation
» Download Public Reports
About 4 000 reports
Company Report: Pathology in The United States and Ireland for Year 2013
- Company report
- May 2013
- 5 pages
- by Corporation
... Involved, even indirectly, with an important therapeutic area that addresses the needs of millions of patients who suffer from respiratory disease is particularly meaningful to all of us at elan." Relvar ...
The French Pharmaceutical Industry Brief
April 2013» Read our Company Profiles
54 CompaniesGlaxoSmithKline P.L.C.
United StatesGlaxoSmithKline PLC
United KingdomJohnson and Johnson
United StatesNovartis Inc.
SwitzerlandSanofi-Aventis Senegal
SenegalReportlinker.com © Copyright 2013. All rights reserved.
